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1. Introduction 
Most liver diseases are caused by host immune responses, and there have been many 
studies on the analysis of circulating lymphocyte subsets and their production of cytokines 
in patients with liver diseases. Although circulating lymphocytes are relatively easy to 
obtain and analyze, analysis of intrahepatic lymphocytes would be more important for 
understanding the immunopathogenesis of liver diseases, especially, viral hepatitis and 
autoimmune liver diseases.  
Two approaches are currently available to analyze intrahepatic lymphocytes in liver biopsy 
specimens, an immunohistochemical approach and a flow cytomeric analysis of isolated 
lymphocytes from liver tissues. Although use of an immunohistochemical approach would 
allow the distribution of particular lymphocyte subsets to be determined, quantitative 
estimation of infiltrating lymphocyte populations may be incorrect. In contrast, flow 
cytometry can determine the precise percentages of each lymphocyte population, but it does 
not provide any information on their intrahepatic distribution. The use of multiple 
antibodies to identify lymphocyte subsets can enable multi-color flow cytometric analysis, 
revealing the precise percentages of each subset, even those constituting an extremely minor 
subset of lymphocytes. Moreover, molecular biological approaches have been used to 
analyze the immunopathogenesis of liver diseases. 
This chapter summarizes findings obtained from the immunological analyses of biopsied 
liver tissues and how immunological analyses of liver biopsy specimens have contributed to 
the understanding of the immunopathogenesis of liver diseases. We also describe recent 
technical advances in the immunological analyses of liver biopsy specimens that can further 
enhance our understanding of the pathogenesis of liver diseases. 
2. Methods for analyzing immunological responses in the liver  
2.1 Immunohistochemical approach (Luttmann et al., 2006) 
Immunohistochemical methods can be used to characterize and localize liver-infiltrating cells 
and proteins such as cytokines, as well as quantitate their degree of infiltration, information 
essential for the analysis of local immune responses. Paraffin-fixed and frozen liver biopsy 
specimens, as well as specimens fixed by other methods, can be analyzed, although the 
immunogenicity of some antigens can be usually better preserved by cryofixation than by 
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chemical fixation. The underlying principle of the immunohistochemical approach is the 
binding of an antigen by a specific antibody (the first antibody). The first antibody is usually 
labeled with a fluorochrome, enzyme, or particle. If an unlabeled antibody is used, the 
secondary antibody must be labeled. Staining with labeled primary antibodies results in better 
detection of antigens, with less nonspecific background staining. Although high 
concentrations of antibodies can detect small amounts of antigens, higher antibody 
concentrations are associated with increased nonspecific binding. Therefore, the specific 
detection of each antigen requires the optimal dilution of each antibody as well as an optimal 
incubation period and temperature. As an example, we describe the immunohistochemical 
detection of antigen, using both a primary and a secondary antibody, in paraffin-fixed tissue 
samples.  
Paraffin-fixed tissue samples must firstly be deparaffinized and rehydrated. Sections are 
then immersed in 10 mM citrate buffer, pH 6.0, and heated in a microwave oven for 
antigen retrieval. Alternatively, sections can be heated in a water bath, autoclave, or steam 
pot, or incubated with proteolytic enzymes, for antigen retrieval. After quenching 
endogenous peroxidase activity with 0.3% H2O2 in methanol, the sections are incubated 
with non-specific proteins, such as normal horse serum or bovine serum albumin, to 
inhibit non-specific finding. The sections are subsequently incubated with primary 
antibodies, either for 30 min at room temperature or overnight at 4˚C, with shorter 
incubation periods usually effective for the detection of specific antigen-antibody binding. 
After rinsing in PBS three times, the sections are incubated with biotinylated secondary 
antibody for 60 min at room temperature, followed by treatment with peroxidase-labeled 
streptavidin for 20 min. Peroxidase activity is developed with 0.25 mg/ml 3,3’-
diaminobenzidine tetrahydrochloride in the presence of 0.003% hydrogen peroxide in 0.05 
M Tris-buffered saline, pH 7.4, and the sections are counterstained for nuclei in 
hematoxylin.  
2.2 Gene expression associated with immune responses in liver biopsy specimen 
In situ hybridization can be used to analyze the expression of specific genes in liver 
biopsy specimens. In addition, the distribution of expression of specific genes in these 
samples can be analyzed by in situ hybridization followed by counter staining for cells 
and organelles.  
In situ hybridization can be performed using both isotope-labeled and non-isotope-labeled 
probes. We briefly describe a non-isotope-labeled method. Tissue samples are digested with 
proteinase and incubated overnight with digoxigenin-labeled riboprobes at 55ºC. The slides 
are then washed in sodium dodecyl sulphate in saline sodium citrate and finally in Tris 
buffered saline containing 0.1% Tween 20 and 1% fetal calf serum (FCS). The tissue samples 
are subsequently incubated with an alkaline phosphatase conjugated antibody against 
digoxigenin. Signal is detected using 5-bromo-4-chloro-3-indoyl phosphatase as a substrate 
and nitro blue tetrazolium as a coupler.  
2.3 Characterization of the phenotypes of isolated intrahepatic lymphocytes (IHLs) 
IHLs can be isolated from liver biopsy specimens by enzymatic digestion and density 
gradient centrifugation (Hata et al., 1990, Doherty et al., 1999). Briefly, tissue samples are 
minced into 1 mm2 pieces and incubated while rotating for 20 min at 37°C in Hank’s 
Balanced Salt Solution (HBSS) containing 0.5 mg/ml collagenase, 0.02 mg/ml DNase, 2% 
FCS and 0.6% bovine serum albumin (BSA). Undigested tissue is removed by filtration 
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through a 100 μm diameter mesh and the cells are washed twice with HBSS. Hepatocytes 
are removed by centrifugation at 30 × g for 1 min and the remaining cells are collected and 
resuspended in RPMI medium containing 10% FCS. Cell yields and viabilities are 
determined by microscopic examination of ethidium bromide/acridine orange stained 
preparations. Yields are usually about 1–2 × 106 mononuclear cells per 200 mg tissue sample, 
a sufficient number of cells for further analyses. 
The phenotype, cytotoxicity (Hata et al., 1990) and cytokine production (Doherty et al., 1999) 
of isolated IHLs can be analyzed by flow cytometry. Moreover, multi-color flow cytometric 
analyses can identify minor populations of lymphocytes and intracytoplasmic cytokines. 
The function of IHLs present in liver biopsy specimens can therefore be analyzed in detail, 
resulting in a comprehensive understanding of intrahepatic immune responses in liver 
diseases. 
2.4 Further application of immunological analysis  
RNA and DNA in liver biopsy specimens can be isolated using commercial kits, followed by 
PCR or RT-PCR for the quantitative evaluation of DNA or RNA encoding proteins 
associated with the immune system.  
Recent advances in microarray technology can be also applied to liver biopsy samples. 
Tissue microarrays are constructed by transferring cores of paraffin-embedded tissue to 
precored holes in a recipient paraffin block (Kononen et al., 1998). Microarray analysis 
enables the evaluation of the expression of multiple genes in liver biopsy specimens in a 
high throughput manner.  
3. Immunological analysis in liver diseases 
Intrahepatic immune responses have been analyzed in liver biopsy specimens, enhancing 
our understanding of the immunopathogenesis of liver diseases.  
3.1 Acute viral hepatitis 
Immunological analysis has been extensively performed in transgenic mouse and 
chimpanzee models of acute infection. In one model, transgenic mice, in which infectious 
HBV virions replicate in the livers with all HBV-related antigens expressed, were injected 
with HBsAg-specific cytotoxic T lymphocytes (CTLs) that had been induced in 
nontransgenic mice. The transgenic mice produced interferon (IFN)- and tumor necrosis 
factor (TNF)- which purged viral RNA and DNA without destroying infected hepatocytes 
(Guidotti et al., 1996, Chisari, 1997, Guidotti et al., 2001). Importantly, this noncytolytic 
clearance of intracellular HBV is more efficient at controlling HBV replication than the 
killing of infected hepatocytes. In this sense, hepatitis is not only a harmful event but also 
represents an effective mechanism by which CTLs suppress HBV. Noncytolytic viral 
eradication can account for recovery from acute HBV infection, in that most HBV is cleared 
from hepatocytes with only a fraction of the hepatocytes being destroyed. This phenomenon 
was confirmed using a chimpanzee infection model. HBV-DNA was profoundly decreased 
in the liver and blood of acutely infected chimpanzees before peak serum alanine 
aminotransferase (ALT) concentrations were reached (Guidotti et al., 1999), suggesting that 
this noncytopathic T cell effector mechanism results in early viral inhibition or eradication, 
whereas a cytopathic T cell effector mechanism would be required to eliminate the 
remaining virus by destroying infected hepatocytes. 
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There have been a limited number of immunological analyses of local immune responses in 
the liver of patients with acute viral hepatitis, due primarily to relative contraindications for 
liver biopsy in these patients. Moreover, the kinetics of local immune response cannot be 
analyzed in humans, because repeated liver biopsies are not usually required and are 
ethically not allowed during the course of acute hepatitis. 
The CD4/CD8 ratio of liver-derived T cell clones was found to be 0.3-0.5 during the acute 
phase of HAV infection, indicating a CD8+ T cell predominance, but 1.2 during the recovery 
phase, indicating a CD4+ T cell predominance (Fleischer et al., 1990). Half of the T cell 
clones showed cytotoxicity against HAV-infected autologous fibroblasts, further suggesting 
that the intrahepatic HAV-specific T cell response has an important role in the pathogenesis 
of acute hepatitis A and in viral eradication.  
Immunohistochemical analysis of intrahepatic lymphocyte populations in patients with 
acute hepatitis A, B and C showed that CD45RO+ memory T cells were the most 
prominent cell population in all 3 types of acute hepatitis, and that the numbers of these 
cells were significantly higher in portal areas of patients with acute hepatitis C than in 
those with acute hepatitis B (Hashimoto et al., 1996). In addition, the ratio of CD20+ B 
cells to CD45RO+ memory T cells was significantly lower in acute hepatitis B than in the 
two other types of acute hepatitis (Hashimoto et al., 1996). These data indicate that 
memory T cells are involved in the immunopathogenesis of all types of acute viral 
hepatitis. However, the clinical significance of the differences among acute hepatitis A, B 
and C remains unclear. 
Recently, the signal delivered by a CD28 superfamily, programmed death-1 (PD-1) protein, 
was shown to impair virus-specific CD8+ T-cell responses during chronic viral infection 
(Watanabe et al., 2010), suggesting that this protein plays an important role in insufficient T 
cell responses against hepatitis viral antigen, leading to persistent viral infection. In patients 
with acute hepatitis C, PD-1 expression was higher on CD4+ than on CD8+ T cells in the 
liver, with expression more prominent on intrahepatic than on peripheral blood 
lymphocytes. However, no correlation was observed between PD-1 expression on T cells 
and clinical outcomes in patients with acute viral hepatitis (Kasprowicz et al., 2008).  
PD-1 expression is thought to be regulated during acute hepatitis, with PD-1 up-regulated 
on CD8+ T cells during the early phase of acute hepatitis B (Zhang et al., 2008). Successful 
viral clearance correlated with a subsequent decrease in PD-1 expression, and the delayed 
PD-1 expression on HBV-specific CD8+ T cells was associated with acute liver failure 
(Zhang et al., 2008), suggesting that impaired regulation of PD-1 expression may lead to 
enhanced immune response and severe hepatitis.  
In summary, intrahepatic viral-specific memory T cells are directly involved in the 
immunopathogenesis of acute viral hepatitis, and the kinetics of PD-1 expression in the liver 
may determine patient outcomes. However, there is limited information on the 
characterization of intrahepatic lymphocytes and on local immune responses in the liver in 
patients with acute viral hepatitis.  
3.2 Chronic hepatitis 
There are few animal models of chronic hepatitis, and most of our knowledge regarding its 
immunopathogenesis is derived from analyses of human liver tissues. Because local 
immune responses cannot be analyzed over time in patients, however, findings obtained 
from animal models may help enhance our understanding of the kinetics of immune 
responses in the liver.  
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Many studies have analyzed intrahepatic lymphocytes in patients with chronic hepatitis, 
both immunohistochemically and by flow cytometry. Most of these studies analyzed the 
makeup of infiltrating cells, the expression of costimulatory molecules in the liver and the 
antigen specificity of infiltrating T cells. These results have greatly contributed to 
understanding the immunopathogenesis of various chronic liver diseases.  
3.2.1 Composition of infiltrating cells 
Chronic hepatitis is characterized by lymphoid cell infiltration mainly in portal tracts. Most 
infiltrating cells are CD3+ T cells, with most of the latter being CD45RO+ memory cells. The 
CD4/CD8 ratio is similar in patients with hepatitis B and C; 50-60% of infiltrating cells are 
CD4+ helper T lymphocytes, around 25% are CD8+ CTLs and 15% are B lymphocytes. CD8+ 
T lymphocytes are located in the peripheral part of portal tracts and intralobular necrotic 
foci (Walewska-Zielecka et al., 2008). Natural killer cells are also involved in the 
immunopathogenesis of chronic hepatitis, with CD3-CD56brightNKG2A+ cells associated 
with necroinflammation of the liver and CD3-CD56dimNKG2A+ cells associated with low 
viral load (Bonorino et al., 2009).  
The percentages of virus-specific T lymphocytes in the liver have been clarified by 
immunohistochemical staining with peptide-MHC tetramer. The proportion of CD8+T 
lymphocytes in the livers of patients with chronic HBV specific for HBc18-27, a major HBV 
epitope, has been found to range from 0.18% to 1.28% (Shimada et al., 2003). In patients with 
chronic hepatitis C, 1-2% of CTLs in the liver were found to be HCV NS3-specific, compared 
with 0.01% to 1.2% of PBLs (He et al., 1999). Due to the low percentages of lymphocyte 
populations specific for viral epitopes, most intrahepatic lymphocytes are thought to be 
antigen-nonspecific. The contribution of virus-specific and -nonspecific cells to hepatocyte 
damage and viral control in chronic viral hepatitis in humans remains unclear. However, in 
the HBV transgenic mouse model of acute hepatitis, administration of antibodies against the 
chemokines, IFN-gamma inducible protein (IP-10) and monokine induced by interferon-
gamma (Mig) reduced the recruitment of mostly Ag-nonspecific mononuclear cells into the 
liver that had been induced by cytokines and chemokines produced by injected CTLs, 
leading to a reduction in the severity of hepatitis without affecting the antiviral activity of 
the CTLs (Kakimi et al., 2001). The findings indicate that CTLs can suppress virus without 
damaging hepatocytes, whereas secondarily recruited mononuclear cells, with little antiviral 
activity, destroy hepatocytes in an Ag-nonspecific manner.  
In humans, several cytokines and chemokines are thought to be involved in the recruitment 
of T lymphocytes into the liver. For example, intrahepatic levels of IP-10/CXCL10 and 
Mig/CXCL19 have been reported to correlate with liver inflammation and fibrosis in the 
livers of patients with chronic hepatitis C (Zeremski et al., 2008). Moreover, their receptor, 
CXCR3, is expressed on most intrahepatic T lymphocytes, indicating that 
chemokine/receptor systems have an important role in T cell recruitment into inflamed 
livers. We have reported that Mip3 produced by DCs after phagocytosis of apoptotic cells 
is chemotactic for CCR6-expressing CD4+ T lymphocytes, but not for CD8+ T lymphocytes 
(Shimizu et al., 2001). A complex chemokine/chemokine receptor network is therefore 
present in the livers of patients with chronic hepatitis, and manipulation of this network 
may control the magnitude of liver inflammation. 
3.2.2 Chronic hepatitis B 
Several studies have characterized CD4+ T lymphocytes in patients with chronic hepatitis B. 
For example, these livers have been found to contain Th0 cells, which produce not only IFN-
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, but also IL-4 and IL-5, thus differing from cells in the livers of patients with chronic 
hepatitis C, which are mostly Th1 cells (Bertoletti et al., 1997).  CD4+ T lymphocytes that 
produce TNF- and IL-17 infiltrate into the livers of patients with chronic hepatitis B and 
are involved in liver inflammation (Zhang et al., 2010). IL-17 producing CD4+ T 
lymphocytes, called Th17 cells, are a third distinct subset of T helper cells and play an 
important role in innate and adoptive immunity and in autoimmunity. In a transgenic 
mouse model, CD4+ T lymphocytes, as well as CD8+ T lymphocytes, have been shown 
effective for noncytolytic viral purge by secreting TNF- and IFN-(Franco et al., 1997). 
Although noncytolytic antiviral mechanism mediated by T lymphocytes was first described 
in a transgenic mouse model (Guidotti et al., 1996), a similar phenomenon was recently 
observed in the livers of patients with chronic hepatitis B.  
The natural history of chronic HBV infection is somewhat complex. Most people infected at 
birth are asymptomatic during their first 20-30 years, called the immune tolerant phase. This 
tolerant phase later breaks down, resulting in ALT flare-ups due to activation of the 
immune response against HBV. After an ALT flare, 80-90% of chronically infected patients 
experience a great reduction, but not a diminishing, of HBV replication, these patients 
seroconvert, from HBeAg to anti-HBe antibody, and become inactive carriers. In the other 
10-20% of chronically infected patients, ALT remains elevated and active HBV replication 
persists, resulting in disease progression to chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma. Although the precise pathogenetic mechanisms differentiating 
inactive carriers from chronic hepatitis patients are unclear, recent immunological analyses 
have provided new insights into the understanding of these mechanisms. 
Livers of patients with low HBV replication contain intralobular CD8+ T lymphocytes (Tang 
et al., 2003), suggesting that the host immune system recognizes viral antigens and may 
carry out immune surveillance in the livers of inactive carriers. Moreover, the same numbers 
of HBcAg-specific CD8+ T lymphocytes are present in the livers of individuals with high 
viral replication/elevated serum ALT and low viral load/normal ALT (Maini et al., 2000), 
suggesting that HBV-specific CD8+ T cells effectively control viral replication without 
damaging infected hepatocytes in inactive carriers, but fails to do so in patients with chronic 
hepatitis. Although the mechanism underlying this failure of viral control remains unclear, 
two possible mechanisms have been hypothesized, one involving regulatory T cells and the 
other involving the costimulatory molecule, PD-1. Regulatory T cells (Tregs) expressing the 
transcription factor Foxp3 are specialized cells that exert negative control on a variety of 
physiological and pathological immune responses, resulting in maintenance of 
immunological self-tolerance (Miyara et al., 2011). Circulating and intrahepatic Tregs are 
involved in persistent infection by hepatitis virus. CD4+CD25+ cells and Foxp3+ cells are 
increased in the livers of patients with chronic hepatitis B (Xu et al., 2006), and patients with 
high viral load have a higher proportion of Tregs in the liver (Stoop et al., 2008), suggesting 
that intrahepatic Tregs suppress antiviral immune responses in the liver.  
PD-1 is a surface receptor critical for the regulation of T cell function (Francisco et al., 2010, 
Fife BT et al., 2011). The binding to PD-1 by its ligands PD-L1 and PD-L2 results in the 
antigen-specific inhibition of T-cell proliferation, cytokine production, and cytolytic 
function. In the liver, PD-1 is expressed on lymphocytes; PD-L1 is expressed on 
lymphocytes, hepatocytes and sinusoidal endothelial cell; and PD-L2 is expressed on 
Kupffer cells and DCs (Chen et al., 2010). Intrahepatic HBV-specific CD8+ T cells express 
higher levels of PD-1, and upregulation of intrahepatic PD-1/PD-L1 is associated with liver 
inflammation and ALT elevation (Fisicaro et al., 2010, Xie et al., 2009). Although the 
www.intechopen.com
 
Immunological Analysis of Liver Diseases with Liver Biopsy Specimens 
 
39 
mechanism underlying the upregulation of PD-1 on CD8+ T cells in inflamed livers is 
unknown, signals from PD-1 inhibit HBV-specific T cells, resulting in insufficient antiviral 
responses and liver inflammation. Importantly, PD-1/PD-L1 blockade increased CD8+ T cell 
proliferation and enhanced IFN-and IL-2 production by intrahepatic lymphocytes (Fisicaro 
et al., 2010). These findings suggest that inhibiting PD-1/PD-L1 may have therapeutic 
potential for the control of hepatitis B. 
Local immune response is also regarded as important during the treatment of hepatitis B. 
The numbers of pretreatment intrahepatic CD8+ T cells has been shown to predict better 
responses to IFN- and lamivudine (Tang et al., 2004, 2005). 
3.2.3 Chronic hepatitis C 
The local immune response occurring in the livers of patients with chronic hepatitis C is 
similar to that in chronic hepatitis B. Intrahepatic CD4+ T cells, most of which are Th1 cells 
producing IFN- but not IL-4 and IL-5 (Bertoletti et al., 1997), are located in portal and 
periportal areas, with the proportions of these cells correlating with histological activity 
index (Fiore et al., 1997). However, no correlation has been found between the proportion of 
intrahepatic CD4+ T cells and viremia or serum ALT levels (Tran et al., 1997). Most 
intrahepatic CD4+ T cells in the livers of patients with chronic hepatitis C are CD45RO+, but 
the percentages of CD4+CD27+ and CD4+CD28+ T cells are lower (Wang et al., 2006), 
suggesting that memory T cells at relatively early stages of differentiation are involved in 
liver inflammation. 
In patients with chronic hepatitis C, CD8+ T cells are located in the lobules within areas of 
inflammation and spotty necrosis, with the proportion correlating with histological 
activity index (Fiore et al., 1997). Intrahepatic CD8+ T cells show higher percentages of 
CCR7+L-selectin- cells, which are distinct from central memory and effector memory cells 
(Heydtmann et al., 2006). The CCR7 ligands CCL19 and CCL21 are expressed on 
sinusoidal endothelial cells, suggesting a mechanism of CD8+ T cell recruitment to the 
inflamed liver. Other chemokine receptors that mediate T cell recruitment are CCR5 and 
CXCR3 (Larrubia et al., 2007). Although the numbers of intrahepatic CD8+ T cells were 
reported to correlate with serum enzyme concentrations, and intralobular CD8+ T cells 
showed weak correlation with serum ALT concentrations (Freeman et al., 2003), 
intrahepatic HCV-specific CD8+ T cells do not secrete IFN- but secrete IL-10, an 
immunosuppressive cytokine (Spangenberg et al., 2005). The presence of these IL-10 
secreting T cells is associated with low levels of hepatocyte apoptosis, ALT and fibrosis 
(Abel et al., 2006). Increased production of IL-10, but not IFN- may result in an 
insufficient anti-HCV response in the liver. 
Similar to intrahepatic T cells in patients with chronic hepatitis B, intrahepatic HCV-specific 
cells were found to express high levels of PD-1 (Radziewicz et al. 2007), which may be 
responsible for the absence of IFN- production, as well as poor proliferation and low 
cytolytic activity. Moreover, large numbers of Foxp3+ cells, mostly CD4+ T cells, are present 
in the portal tracts of the livers of patients with chronic hepatitis C (Ward et al., 2007, 
Claassen et al., 2010, Sturm et al., 2010). These cells are also in contact with CD8+ T cells in 
necro-inflammatory areas, suggesting that CD8+ T cells are inhibited by cell-cell contact 
with Tregs (Sturm et al., 2010). These immunosuppressive mechanisms present in the livers 
of patients with chronic hepatitis C may be responsible for persistent HCV infection despite 
the presence of HCV-specific T cells in the liver. 
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In addition to T cells, livers of patients with chronic hepatitis C often contain lymphoid 
follicles in portal tracts, a characteristic of HCV-infected livers. We previously reported that 
functional and clonal expansion of B cells occurs in lymphoid follicles with germinal centers 
in HCV-infected livers (Murakami et al., 1999), although the antigen specificity of these B 
cells is unclear. 
Local immune responses may be involved in viral eradication during patient treatment with 
IFN. The numbers of pretreatment CD8+ T cells in portal tracts and intrahepatic HCV-
specific CD8+ CTLs have been reported associated with a better response to IFN- or a 
sustained virological response (Nelson et al., 1998, Vrolijk et al., 2003). Therefore, 
upregulation of intrahepatic T cell response may enhance the effectiveness of antiviral 
treatment. 
3.3 Autoimmune liver disease 
The dominant population of intrahepatic T cells in patients with primary biliary cirrhosis 
has been reported to be CD4+TCR+ T cells, whereas the dominant population in patients 
with chronic hepatitis B and C has been reported to be CD8+TCR+ T cells (Löhr et al., 
1994). This finding, however, remains controversial and it does not help distinguish 
autoimmune liver disease from viral hepatitis. 
3.3.1 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) 
The liver histology of patients with PBC has been extensively analyzed. A characteristic 
early stage histologic feature in these patients is nonsuppurative destructive cholangitis. 
Although the biliary epithelium is thought to be the target for host immune responses, the 
mechanism underlying epithelial destruction is unclear. CD8+ T cells are present within 
the bile duct epithelial layer of patients with chronic nonsuppurative destructive 
cholangitis, suggesting that CTLs destroy the bile duct epithelium. B7-2 (CD86), but not 
B7-1 (CD80), expression has been observed in bile duct epithelium during early stages of 
PBC and PSC (Tsuneyama et al., 1998), suggesting that bile duct epithelium may act as 
antigen-presenting cells. Immunopathologically important target antigens have not been 
determined. Although the generation of anti-mitochondrial antibodies is important for the 
diagnosis of PBC, mitochondrial antigens are not thought to be the pathogenetic target for 
immune cells. Livers of patients with PBC have been reported to contain more Tregs than 
livers of patients with autoimmune hepatitis (Sasaki et al., 2008), with Tregs infiltrating 
into the biliary epithelial layer during chronic nonsuppurative destructive cholangitis 
(Sasaki et al., 2007). Moreover, the numbers of Foxp3+ Tregs were found to parallel the 
degree of portal inflammation. These results, showing the presence of Tregs in the livers 
of patients with PBC and that their regulatory functions are not reduced in the livers of 
patients with PBC and PSC, suggest that autoimmunity in PBC is not due to a reduction in 
Treg function.  
PD-1 expression has also been assayed in livers of patients with PBC. PD-1 is expressed on 
more than 50% of intrahepatic T lymphocytes in the portal tracts, but their levels of 
expression are lower than in patients with autoimmune hepatitis (Oikawa et al., 2007).  
3.3.2 Autoimmune hepatitis (AIH) 
CD4+ T cells and CD20+ B cells have been reported to be located in the center of portal 
areas, with CD8+ T cells at the periphery of the portal area (De Biasio et al., 2006). Although 
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CD4+ T cells constitute the major population of intrahepatic lymphocytes, many CD80+, 
CD86+ and CD152+ cells are present in the livers of patients with autoimmune hepatitis 
(Kurokochi et al., 2006). Moreover, patients with high levels of intrahepatic CD86+ cells 
showed good responses to corticosteroids (Kurokochi et al., 2006).  
One of the putative target antigens in the immunopathogenesis of autoimmune hepatitis is 
asialoglycoprotein receptor, and antibodies against this receptor are often present in patients 
with autoimmune hepatitis. Although the mechanism of antibody production is unknown, 
intrahepatic T helper cells in patients with autoimmune hepatitis can stimulate the 
production of the autoantibody. Few Tregs are observed in these livers, with those present 
having impaired function (Longhi et al., 2010), suggesting that decreased functional activity 
of Tregs may predispose to enhanced autoimmune reactions. 
3.4 Nonalcoholic fatty liver disease 
Nonalcoholic fatty liver disease (NAFLD) is a frequently occurring chronic liver disease and 
can range in intensity from simple steatosis to nonalcoholic steatohepatitis (NASH). Due to 
chronic necro-inflammatory changes, patients with NASH may develop cirrhosis or 
hepatocellular carcinoma, although these are rare in patients with simple steatosis. 
Histologically, steatosis (usually >5% per liver tissue section), cellular injury such as 
ballooned hepatocytes or Mallory-Denk bodies, and accompanying lobular inflammation 
are observed in the livers of patients with NAFLD. Inflammatory infiltrates in these livers 
consist predominantly of lymphocytes, as well as plasma cells and polymorphonuclear 
leucocytes in portal tracts of the liver (Brunt et al., 2010). The ‘two-hit theory’ is widely 
accepted in the pathogenesis of NAFLD, and patients with simple steatosis are regarded as 
not showing disease progression because of the absence of the second hit (Day et al., 1998). 
Adipocytokines from adipose tissue and gut-derived factors (i.e. endotoxin) are regarded as 
the principal pathogenetic factors, the second hits, in the disease progression of NAFLD 
(Tilg et al., 2010), but recent reports have revealed that immunological mechanisms are 
directly involved in its pathogenesis. An immunohistochemical analysis of liver biopsy 
specimens showed that cells of the innate immune system, including neutrophils, 
macrophages (Kupffer cells) and NKT cells, are involved in the pathogenesis of NAFLD. 
Livers of patients with NASH showed increased hepatic neutrophil infiltration and 
increased hepatic expression of mRNAs coding for proinflammatory cytokines, as 
determined by quantitative RT-PCR. Furthermore, activation of the complement system in 
the liver is associated with the severity of NAFLD (Rensen et al., 2009). In rodent models of 
NAFLD, activation of Kupffer cells and proinflammatory cytokines are involved in disease 
progression (Maher et al., 2008, Syn et al., 2009). Kupffer cells are thought to be activated by 
gut-derived factors, adipocytokines and apoptotic cells, and to produce proinflammatory 
cytokines and reactive oxygen species (ROS). Proinflammatory cytokines and ROS may 
induce insulin resistance, which is regarded as important in the development of NAFLD. In 
addition, recent studies by our group and others have found that accumulation of NKT cells 
in the liver is associated with disease progression to NASH (Fig. 1), suggesting that NKT 
cells may contribute to disease progression in NAFLD (Tajiri et al., 2009, Syn et al., 2010). 
CD1d, a molecule essential for the activation and maintenance of NKT cells (Godfrey et al., 
2004), is highly expressed on activated macrophages in the livers of NASH patients (Tajiri et 
al., 2009), suggesting that NKT and Kupffer cells may interact during the pathogenesis of 
NAFLD (Fig. 2).  
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Fig. 1. Immunological analysis of liver biopsy specimens in patients with NAFLD. 
(A) Samples were stained with monoclonal antibody against CD56 in patients with (left 
panel) simple steatosis and (right panel) NASH. (B) Flow cytometric analysis of 
mononuclear cells isolated from livers of patients with (left panel) simple steatosis and 
(right panel) NASH. The numbers in each quadrant represent the percentages of 
mononuclear cells. Right-upper quadrant represents NKT (CD3+CD56+) cells. 
 
 
ROS: reactive oxygen species 
Fig. 2. Hypothesis of the pathogenesis of NAFLD.  
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4. Conclusion 
Although analysis of intrahepatic immune response is difficult to be performed, valuable 
information on the immunopathogenesis of liver diseases could be obtained. Accumulation 
of the findings would finally lead to a novel immunotherapeutic approach for the 
management of various liver diseases. 
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